The activating receptor NKp46 is essential for the development of type 1 diabetes

Nature Immunology

Volumn 11, Issue 2, 2010, Pages 121-128

  Gur, Chamutal ^a,b   Porgador, Angel ^c   Elboim, Moran ^a   Gazit, Roi ^a   Mizrahi, Saar ^a   Stern Ginossar, Noam ^a   Achdout, Hagit ^a   Ghadially, Hormas ^a   Dor, Yuval ^a   Nir, Tomer ^a   Doviner, Victoria ^b   Hershkovitz, Oren ^c   Mendelson, Michal ^c   Naparstek, Yaakov ^b   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LYMPHOCYTE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKP46; NATURAL KILLER CELL RECEPTOR NKP46 IMMUNOGLOBULIN FUSION PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG; AUTOANTIGEN; LY ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NCR1 PROTEIN, HUMAN; NCR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL LINE; CONTROLLED STUDY; DEGRANULATION; DISEASE COURSE; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALS; ANTIGENS, LY; AUTOANTIGENS; CELL DEGRANULATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-SECRETING CELLS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1;

EID: 75649104301     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1834     Document Type: Article

References (37)

1. Delovitch, T.L. & Singh, B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7, 727-738 (1997).
2. Kikutani, H. & Makino, S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51, 285-322 (1992).
3. Like, A.A. & Rossini, A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415-417 (1976).
4. O'Brien, B.A., Harmon, B.V., Cameron, D.P. & Allan, D.J. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J. Pathol. 178, 176-181 (1996).
5. Paik, S.G., Fleischer, N. & Shin, S.I. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc. Natl. Acad. Sci. USA 77, 6129-6133 (1980).
6. Hutchings, P. et al. Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 348, 639-642 (1990).
7. Miyazaki, A. et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin. Exp. Immunol. 60, 622-630 (1985).
8. Dotta, F. et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc. Natl. Acad. Sci. USA 104, 5115-5120 (2007).
9. Rodacki, M. et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 56, 177-185 (2007).
10. Poirot, L., Benoist, C. & Mathis, D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc. Natl. Acad. Sci. USA 101, 8102-8107 (2004).
11. Alba, A. et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-β. Clin. Exp. Immunol. 151, 467-475 (2008).
12. Flodstrom, M., Shi, F.D., Sarvetnick, N. & Ljunggren, H.G. The natural killer cell-friend or foe in autoimmune disease? Scand. J. Immunol. 55, 432-441 (2002).
13. Hansson, M., Kiessling, R. & Andersson, B. Human fetal thymus and bone marrow contain target cells for natural killer cells. Eur. J. Immunol. 11, 8-12 (1981).
14. Nakamura, N. et al. Intrinsic cytotoxicity of natural killer cells to pancreatic islets in vitro. Diabetes 39, 836-843 (1990).
15. Morse, R.H., Seguin, R., McCrea, E.L. & Antel, J.P. NK cell-mediated lysis of autologous human oligodendrocytes. J. Neuroimmunol. 116, 107-115 (2001).
16. Karre, K. NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. 55, 221-228 (2002).
17. Ogasawara, K. et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18, 41-51 (2003).
18. Gazit, R. et al. Lethal infuenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7, 517-523 (2006).
19. Moretta, L. Lymphocyte effector mechanisms in innate and adaptive immunity. Curr. Opin. Immunol. 17, 303-305 (2005).
20. Satoh-Takayama, N. et al. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J. Immunol. 183, 6579-6587 (2009).
21. Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757-767 (2004).
22. Maier, L.M. et al. NKG2D-RAE-1 receptor-ligand variation does not account for the NK cell defect in nonobese diabetic mice. J. Immunol. 181, 7073-7080 (2008).
23. Moretta, A., Bottino, C., Mingari, M.C., Biassoni, R. & Moretta, L. What is a natural killer cell? Nat. Immunol. 3, 6-8 (2002).
24. Mandelboim, O. et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409, 1055-1060 (2001).
25. Arnon, T.I. et al. The mechanisms controlling the recognition of tumor-and virus-infected cells by NKp46. Blood 103, 664-672 (2004).
26. Aktas, E., Kucuksezer, U.C., Bilgic, S., Erten, G. & Deniz, G. Relationship between CD107a expression and cytotoxic activity. Cell. Immunol. 254, 149-154 (2009).
27. Alter, G., Malenfant, J.M. & Altfeld, M. CD107a as a functional marker for the identifcation of natural killer cell activity. J. Immunol. Methods 294, 15-22 (2004). (Pubitemid 39626587)
28. Flodstrom, M., Tyrberg, B., Eizirik, D.L. & Sandler, S. Reduced sensitivity of inducible nitric oxide synthase-deffcient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48, 706-713 (1999).
29. Lodoen, M. et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197, 1245-1253 (2003).
30. Halfteck, G.G. et al. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 182, 2221-2230 (2009).
31. Kitagawa, Y. et al. Islet cells but not thyrocytes are susceptible to lysis by NK cells. J. Autoimmun. 4, 703-716 (1991).
32. MacKay, P., Jacobson, J. & Rabinovitch, A. Spontaneous diabetes mellitus in the Bio-Breeding/Worcester rat. Evidence in vitro for natural killer cell lysis of islet cells. J. Clin. Invest. 77, 916-924 (1986).
33. Foulis, A.K., McGill, M., Farquharson, M.A. & Hilton, D.A. A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 40, 53-61 (1997).
34. Horwitz, M.S. et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4, 781-785 (1998).
35. Lodde, B.M. et al. NOD mouse model for Sjogren's syndrome: lack of longitudinal stability. Oral Dis. 12, 566-572 (2006).
36. Matsumoto, S. et al. Isolation of tissue progenitor cells from duct-ligated salivary glands of swine. Cloning Stem Cells 9, 176-190 (2007).
37. Baert, F. et al. Infuence of immunogenicity on the long-term effcacy of infiximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003).